Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
6
×
biotech
6
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
6
×
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
novartis
clinical trials
diagnostics
eli lilly
merck
pfizer
abbvie
alder biopharmaceuticals
alzheimer's disease
calcitonin gene-related peptide
cancer
cystic fibrosis
What
drug
6
×
new
bio
roundup
acquisitions
approval
biggest
ceo
class
drugs
fda
migraine
patients
won
advantages
albert
amgen
arguments
bar
big
bourla
brings
build
buy
candidates
cholesterol
commercialized
companies
company
company’s
competitors
crispr
daniel
debut
decades
developed
dyne’s
expect
expensive
faces
Language
unset
unknown
Current search:
drug
×
biotech
×
amgen
×
" seattle blog main "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines